Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abzena Signs Protein Engineering Agreement with NYU Langone Health | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Abzena Signs Protein Engineering Agreement with NYU Langone Health

Tie-up centers around development of biopharmaceutical being developed for autoimmune disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abzena has entered into a master service agreement with one of America’s leading academic medical centers, NYU Langone Health. The agreement, for protein engineering and drug discovery services, will help NYU Langone’s drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics.

The first project under this master agreement centers around the development of a novel biopharmaceutical being developed by NYU OTA for the treatment of severe autoimmune disease. Abzena will provide integrated development support from its bioassay, immunology and protein engineering groups.

“It’s fantastic that our expertise and integrated offering across our biology group is being used in the development of another promising treatment,” said Dr. Campbell Bunce, senior vice president, scientific operations, Abzena. “This agreement represents another example of Abzena supporting exciting drug candidates from academic groups, utilizing not just our services but also our significant biologics know-how.”

Dr. Nadim Shohdy, assistant dean and director, therapeutics alliances, NYU Langone, said, “We are very excited to execute both the master agreement, and to launch this inaugural project with Abzena. This partnership will augment NYU Langone’s access to deep biologics capabilities and expertise to further enhance OTA’s mission to translate the research of our faculty into therapeutic products that help patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics